Hajna Losonczy

993 total citations
50 papers, 686 citations indexed

About

Hajna Losonczy is a scholar working on Hematology, Genetics and Internal Medicine. According to data from OpenAlex, Hajna Losonczy has authored 50 papers receiving a total of 686 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 15 papers in Genetics and 11 papers in Internal Medicine. Recurrent topics in Hajna Losonczy's work include Chronic Lymphocytic Leukemia Research (13 papers), Blood Coagulation and Thrombosis Mechanisms (11 papers) and Venous Thromboembolism Diagnosis and Management (11 papers). Hajna Losonczy is often cited by papers focused on Chronic Lymphocytic Leukemia Research (13 papers), Blood Coagulation and Thrombosis Mechanisms (11 papers) and Venous Thromboembolism Diagnosis and Management (11 papers). Hajna Losonczy collaborates with scholars based in Hungary, France and Germany. Hajna Losonczy's co-authors include Orsolya Tóth, Sandra Penz, Wolfgang Siess, Tímea Berki, Pèter Németh, Ágnes Nagy, László Pótó, Ágnes Péterfalvi, Gábor L. Kovaćs and I. Nagy and has published in prestigious journals such as Blood, Life Sciences and British Journal of Haematology.

In The Last Decade

Hajna Losonczy

46 papers receiving 662 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hajna Losonczy Hungary 9 324 258 187 152 64 50 686
R. Großmann Germany 16 301 0.9× 352 1.4× 203 1.1× 239 1.6× 63 1.0× 36 785
Akio Hirayama Japan 8 147 0.5× 266 1.0× 157 0.8× 112 0.7× 55 0.9× 23 690
A. Schwarz Germany 6 232 0.7× 409 1.6× 190 1.0× 141 0.9× 69 1.1× 6 795
Geneviève Freyburger France 12 273 0.8× 264 1.0× 252 1.3× 105 0.7× 30 0.5× 31 632
M. Blombäck Sweden 18 185 0.6× 552 2.1× 168 0.9× 133 0.9× 102 1.6× 46 1.0k
H. Lackner United States 17 277 0.9× 240 0.9× 125 0.7× 299 2.0× 76 1.2× 29 873
Paula F. Ypma Netherlands 15 162 0.5× 464 1.8× 121 0.6× 63 0.4× 140 2.2× 57 770
G Patrassi Italy 18 113 0.3× 460 1.8× 179 1.0× 235 1.5× 104 1.6× 68 953
Chika Uotani Japan 18 201 0.6× 363 1.4× 188 1.0× 156 1.0× 67 1.0× 45 749
Anna Ågren Sweden 14 347 1.1× 175 0.7× 270 1.4× 92 0.6× 19 0.3× 28 718

Countries citing papers authored by Hajna Losonczy

Since Specialization
Citations

This map shows the geographic impact of Hajna Losonczy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hajna Losonczy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hajna Losonczy more than expected).

Fields of papers citing papers by Hajna Losonczy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hajna Losonczy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hajna Losonczy. The network helps show where Hajna Losonczy may publish in the future.

Co-authorship network of co-authors of Hajna Losonczy

This figure shows the co-authorship network connecting the top 25 collaborators of Hajna Losonczy. A scholar is included among the top collaborators of Hajna Losonczy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hajna Losonczy. Hajna Losonczy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rosta, András, Hajna Losonczy, Miklós Egyed, et al.. (2017). Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study). Pathology & Oncology Research. 24(2). 199–205. 4 indexed citations
2.
Gindele, Réka, György Pfliegler, László Nemes, et al.. (2017). Clinical and laboratory characteristics of antithrombin deficiencies: A large cohort study from a single diagnostic center. Thrombosis Research. 160. 119–128. 16 indexed citations
3.
Péterfalvi, Ágnes, et al.. (2013). Challenges in the evaluation of D-dimer and fibrinogen levels in pregnant women. Thrombosis Research. 131(4). e183–e187. 38 indexed citations
4.
Magyarlaki, Tamás, Gábor Kovács, Ágnes Nagy, et al.. (2008). Multidrug resistance in chronic lymphocytic leukemia. Orvosi Hetilap. 149(4). 161–167. 3 indexed citations
5.
6.
Penz, Sandra, et al.. (2006). Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood. Thrombosis and Haemostasis. 96(12). 781–788. 433 indexed citations
7.
Szilágyi, András, et al.. (2005). Two Successful Pregnancies following Eight Miscarriages in a Patient with Antithrombin Deficiency. Gynecologic and Obstetric Investigation. 61(2). 111–114. 8 indexed citations
8.
Losonczy, Hajna, et al.. (2005). Prevalence and Clinical Significance of Single and Combined Inherited Thrombophilias.. Blood. 106(11). 1632–1632.
9.
Tóth, Orsolya, Marianna Dávid, Tamás Habon, et al.. (2005). [Type I antithrombin deficiency as a cause of arterial and venous thrombosis in a family with severe thrombophilia].. PubMed. 146(41). 2121–5. 1 indexed citations
10.
Pajor, László, et al.. (2004). Increased incidence of monoclonal B-cell infiltrate in chronic myeloproliferative disorders. Modern Pathology. 17(12). 1521–1530. 7 indexed citations
11.
Rák, Kálmán, et al.. (2003). [Conclusions of consensus development conferences on the prevention and treatment of venous thromboembolism].. PubMed. 144(29). 1427–31. 1 indexed citations
12.
Berki, Tímea, et al.. (2001). New diagnostic tool for differentiation of idiopathic hypereosinophilic syndrome (HES) and secondary eosinophilic states. Pathology & Oncology Research. 7(4). 292–297. 7 indexed citations
13.
Melegh, Béla, et al.. (1998). [Incidence of factor V G1681A (Leiden) mutation in samplings from the Hungarian population].. PubMed. 139(19). 1161–3. 5 indexed citations
14.
15.
16.
Losonczy, Hajna & I. Nagy. (1987). Activation of haemostasis by combined chemotherapy.. PubMed. 44(1). 83–103. 2 indexed citations
17.
Losonczy, Hajna, et al.. (1984). The effects of various doses and various applications of heparin on the fat metabolism and on blood coagulation.. PubMed. 96(24). 885–9. 1 indexed citations
18.
Losonczy, Hajna, et al.. (1979). An analysis of clinical and laboratory data in patients with congenital antithrombin III (AT III) deficiency.. PubMed. 36(1). 53–60. 13 indexed citations
19.
Losonczy, Hajna, et al.. (1975). [Recurrent thromboembolism in children caused by hereditary antithrombin III deficiency].. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 102(2). 233–7. 1 indexed citations
20.
Nagy, I. & Hajna Losonczy. (1975). The Significance of the Chronic Anticoagulant Treatment in Recurrent Thromboembolic Caused by Hereditary Antithrombin III Deficiency. Thrombosis and Haemostasis. 34(1). 366–366. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by R. Großmann Breakdown of academic impact, for papers by Akio Hirayama Breakdown of academic impact, for papers by A. Schwarz Breakdown of academic impact, for papers by Geneviève Freyburger Breakdown of academic impact, for papers by M. Blombäck Breakdown of academic impact, for papers by H. Lackner Breakdown of academic impact, for papers by Paula F. Ypma Breakdown of academic impact, for papers by G Patrassi Breakdown of academic impact, for papers by Chika Uotani Breakdown of academic impact, for papers by Anna Ågren
Rankless by CCL
2026